UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prognostic Significance of Patient-Reported Outcomes in Cancer

JCO oncology practice, 2020-04, Vol.16 (4), p.e313-e323

2020

Volltextzugriff (PDF)

Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report

Case reports in oncology, 2019-09, Vol.12 (3), p.866-871

2019

Volltextzugriff (PDF)

Synergistic Toxicities from Multiple Therapies for Synchronous Malignancies

Case reports in oncology, 2023-01, Vol.16 (1), p.45-48

2023

Volltextzugriff (PDF)

Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy

Journal of oncology pharmacy practice, 2020-01, Vol.26 (1), p.224-227

2020

Volltextzugriff (PDF)

Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group

Journal of the National Comprehensive Cancer Network, 2022-01, Vol.20 (13), p.1-6

2022

Volltextzugriff (PDF)

Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma

Journal of Oncology, 2015-01, Vol.2015 (2015), p.370-375

2015

Volltextzugriff (PDF)

Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?

Journal of thoracic disease, 2018-03, Vol.10 (3), p.1198-1200

2018

Volltextzugriff (PDF)

Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

BMC urology, 2017-01, Vol.17 (1), p.1-1, Article 1

2017

Volltextzugriff (PDF)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer

OncoTargets and therapy, 2016-01, Vol.9 (Issue 1), p.75-86

2016

Volltextzugriff (PDF)

A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy

Journal of radiation oncology, 2018-09, Vol.7 (3), p.223-232

2018

Volltextzugriff (PDF)

Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy

Leukemia & lymphoma, 2011-07, Vol.52 (7), p.1211-1214

2011

Volltextzugriff (PDF)

Correlation of Degree of Hypothyroidism With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors

Clinical genitourinary cancer, 2015-06, Vol.13 (3), p.e131-e137

2015

Volltextzugriff (PDF)

Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies

Clinical genitourinary cancer, 2016-04, Vol.14 (2), p.153-159

2016

Volltextzugriff (PDF)

Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors

Journal of oncology pharmacy practice, 2018-04, Vol.24 (3), p.190-197

2018

Volltextzugriff (PDF)

YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3034-3034

2024

Volltextzugriff (PDF)

Potential surrogates for performance status and survival in metastatic non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.170-170

2021

Volltextzugriff (PDF)

Heart rate: Activity mismatch as a prognostic marker of survival in metastatic non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.190-190

2021

Volltextzugriff (PDF)

Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9005-9005

2022

Volltextzugriff (PDF)

Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8515-8515

2022

Volltextzugriff (PDF)

Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide TM

Neuro-oncology advances, 2024-01, Vol.6 (1), p.vdad150

2024

Volltextzugriff (PDF)

Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9610-9610

2020

Volltextzugriff (PDF)

Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL)

Journal of clinical oncology, 2018-10, Vol.36 (30_suppl), p.303-303

2018

Volltextzugriff (PDF)

Prognostic value of patient-reported outcomes (PROs) in advanced cancer

Journal of clinical oncology, 2018-10, Vol.36 (30_suppl), p.8-8

2018

Volltextzugriff (PDF)

Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.10101-10101

2018

Volltextzugriff (PDF)

Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.608-608

2016

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(52)
Berichte
(2)

Sprache

Englisch
(54)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Oncology
(13)
Humans
(10)
Male
(6)
Female
(5)
Immunotherapy
(5)
Metastasis
(5)
Middle Aged
(5)
Patients
(5)
Urology
(4)
Urology & Nephrology
(4)
Adult
(3)
Aged
(3)
Biotechnology & Applied Microbiology
(3)
Carcinoma, Renal Cell - Drug Therapy
(3)
Chemotherapy
(3)
Hematology, Oncology And Palliative Medicine
(3)
Kidney Cancer
(3)
Kidney Neoplasms - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic Significance of Patient-Reported Outcomes in Cancer

Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report

Synergistic Toxicities from Multiple Therapies for Synchronous Malignancies

Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy

Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group

Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma

Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?

Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer

A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy

Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy

Correlation of Degree of Hypothyroidism With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors

Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies

Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors

YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial

Potential surrogates for performance status and survival in metastatic non-small cell lung cancer (NSCLC)

Heart rate: Activity mismatch as a prognostic marker of survival in metastatic non-small cell lung cancer (NSCLC)

Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study

Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC)

Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide TM

Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study

Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL)

Prognostic value of patient-reported outcomes (PROs) in advanced cancer

Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer

Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC)

Suchergebnisse filtern